Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Capilliposide A is a triterpenoid saponin compound isolated from the traditional Chinese medicinal plant *Lysimachia capillipes* Hemsl. While most available research focuses on related compounds such as Capilliposide B and C, which have demonstrated anticancer, anti-inflammatory, and analgesic activities in preclinical models, there is limited specific published data on Capilliposide A itself. The broader class of capilliposides has been shown to inhibit cancer cell proliferation by inducing reactive oxygen species (ROS) generation, cell cycle arrest (notably at the S phase), and apoptosis through mitochondrial pathways[3][9]. These compounds are also reported to have analgesic and anti-inflammatory effects in animal models[4]. The exact mechanism of action for Capilliposide A specifically is not well-documented in the literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on capilliposide a.